BioSpace News Archive

The Parliamentary Secretary to the Minister of Health, Pam Damoff, will announce new support from the Government of Canada for Canadians living with Autism Spectrum Disorder and those who care for them.

Online mail-order pharmacy selected for “Healthcare in America” documentary

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the acceptance of an oral late breaking presentation providing updated melflufen data from the Phase 2 pivotal OP-106 HORIZON study as well as two poster presentations at the 17th International Myeloma Workshop (IMW) meeting (September 12-15, Boston, Massachusetts, USA).

CVRx, Inc., a private medical device company, announced today that it has received Premarket Approval (PMA) from the United States Food and Drug Administration (FDA) to market its BAROSTIM NEO device for heart failure in the United States.

Health Perspectives Group, a health engagement company that unites patients, providers and the companies that serve them, has been ranked for the third year in a row as one of America’s fastest-growing private companies by Inc. Magazine on its 38th annual Inc. 5000 list.

Inc. magazine revealed that NativePath, formally known as Lexicon Health, is No. 655 on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies.

Onco360®, the nation’s largest independent Oncology Pharmacy, announced today that it was selected to be a specialty pharmacy network partner for Celgene’s new product Inrebic® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF)

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease (PAD and CAD), presented three-year outcomes from its LIBERTY 360° study in a late-breaking presentation at the 2019 Amputation Prevention Symposium (AMP) in Chicago.

Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the second quarter ended June 30, 2019.